[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368087-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368087-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","virotherapy-as-gene-deliver-for-anti-cancer-therapy-a-review-article","Virotherapy as Gene Deliver for Anti-Cancer Therapy - A Review Article","","This narrative review identifies Adenovirus (AdV) as a leading gene-therapy candidate for anti-cancer virotherapy, citing high transduction efficiency, large gene-carrying capacity, and evidence of advancement to phase III clinical trials. Limitations stem from heterogeneity in study designs, possible publication bias, and potential exclusion of relevant studies. As vector technologies evolve, future work should improve vector safety, targeting specificity, and long-term outcomes to maximize therapeutic potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/virotherapy-as-gene-deliver-for-anti-cancer-therapy-a-review-article/368087/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/virotherapy-as-gene-deliver-for-anti-cancer-therapy-a-review-article/368087.png","ImageObject",300,407,{"name":42,"@type":43},"pixelkiddo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which viral vector is highlighted as the leading candidate in this review, and why?","Question",{"text":63,"@type":64},"Adenovirus (AdV) is highlighted due to its high transduction efficiency, large gene-carrying capacity, and evidence progressing to phase III clinical trials.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are the key limitations of the review’s interpretation?",{"text":68,"@type":64},"Interpretation is limited by variations in study designs, potential publication bias, and possible exclusion of relevant studies.",{"name":70,"@type":61,"acceptedAnswer":71},"How do retroviruses, Adenovirus (AdV), and AAV differ in reported transduction efficiency and gene capacity?",{"text":72,"@type":64},"Retroviruses show 40%–60% efficiency with 37 kb integration-capable delivery; AdV reports ~98% in hepatocellular carcinoma and 70%–80% in other cancers with 37 kb capacity without integration; AAV reports 30%–50% efficiency with 4.8 kb capacity and therapeutic potential.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368087,1790808080,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","REVIEW  \n\n| Editorial Proc | ess: Submission:12/11/2024 Acceptance:11/17/2025 Published:11/20/2025 |\n| --- | --- |\n\nVirotherapy as Gene Deliver for Anti-Cancer Therapy: AReview Article  \nFakhren Nukha Zalfa, Nurul Hikma Suciani, Putu Ananda Arviana Dewi, Anissafa Atul Khusna, Rima Nurlita, Dion BishmaDaniswara, Anisa Oktaviana Putri, Muh. Ade Artasasta*  \nAbstract  \nThis review identifies Adenovirus (AdV) as a leading candidate for gene therapy due to its high transduction efficiency and large gene-carrying capacity, supported by evidence of its progression to phase III clinical trials. However, the interpretation of findings is limited by variations in study designs, potential publication bias, and possible exclusion of relevant studies. As the field continues to evolve with new vector technologies, future research should focus on improving vector safety, specificity, and long-term outcomes to maximize the therapeutic potential of virotherapy. Objective: Cancer is the second leading cause of death worldwide. Treatments like chemotherapy and radiotherapy are commonly used, but they have side effects and complications. Gene therapy, using viral vectors like retroviruses, Adenovirus (AdV), and Adeno-Associated Virus (AAV), offers a new approach to overcome these limitations by specifically targeting cancer cells’ genetics. This article was developed as a review to compare the effectiveness of different viruses in virotherapy for cancer treatment. Methods: This article employed a narrative literature review and qualitative content analysis to synthesize current knowledge on the topic. More than 85 peer-reviewed articles published between 2016 and 2024 were collected from databases such as ScienceDirect, PubMed, Scopus, and Nature. The search used relevant keywords with Boolean operators (AND, OR) torefine results. Articles were selected based on language (English), publication type (peer-reviewed), and relevance to the topic. The selected literature was analyzed to identify recurring patterns, key themes, and significant insights. Result: The research results indicate that viruses demonstrated vary levels of efficacy. Retroviruses have a 40%-60% transduction efficiency, can integrate into the host genome, and infect only dividing cells. Adenovirus (AdV) has a 98% efficiency in hepatocellular carcinoma and 70% - 80% in other cancers, delivers genetic material without integration, infects both dividing and non-dividing cells, and has a gene capacity of 37 kb. Adeno-Associated Virus (AAV) has a 30%-50% efficiency, a gene capacity of 4.8 kb, and also shows therapeutic potential. Conclusion: Each virotherapy agent used in gene therapy exhibits varying efficacy against cancer cells, indicating specific mechanisms unique to each virotherapy agent.  \nKeywords: Adenovirus-Adeno-Associated Virus-Cancer-Retrovirus-Viral Vector  \nAsian Pac J Cancer Prev, 26 (11), 3895-3907  \nIntroduction  \nCancer is one of the diseases with the second highest death rate in the world with 8.97 million deaths after ischemic heart disease and is expected to continue to increase. The number of cancer cases recorded is almost 20 million new cases in 2022 and 9.7 million deaths due to cancer worldwide, this figure has increased from the previous year which was 18 million cases in 2018 and continuing to increase every year.  \nIn the last few decades, several combinations of therapies have been suggested and are currently used to treat various types of cancer [1] . Chemotherapy and conventional radiotherapy are now widely utilized,  \nwhich were not common a few years ago [2] . Although chemotherapy and radiotherapy are the primary treatments for cancer, their effectiveness and application are often hindered by severe side effects [3].These side effects directly reduce patients’ quality of life and may also lead to long-term complications in cancer survivor [4],[5] .  \nGene therapy is a cutting-edge treatment method that involves introducing new genes into cancerous ","cbCaig5NOJsGhUxa","https://ap.wps.com/l/cbCaig5NOJsGhUxa","pdf",1511296,13,"English","# Abstract\n# Introduction\n## Global cancer burden and current therapies\n## Gene therapy and virotherapy with viral vectors","[{\"question\":\"Which viral vector is highlighted as the leading candidate in this review, and why?\",\"answer\":\"Adenovirus (AdV) is highlighted due to its high transduction efficiency, large gene-carrying capacity, and evidence progressing to phase III clinical trials.\"},{\"question\":\"What are the key limitations of the review’s interpretation?\",\"answer\":\"Interpretation is limited by variations in study designs, potential publication bias, and possible exclusion of relevant studies.\"},{\"question\":\"How do retroviruses, Adenovirus (AdV), and AAV differ in reported transduction efficiency and gene capacity?\",\"answer\":\"Retroviruses show 40%–60% efficiency with 37 kb integration-capable delivery; AdV reports ~98% in hepatocellular carcinoma and 70%–80% in other cancers with 37 kb capacity without integration; AAV reports 30%–50% efficiency with 4.8 kb capacity and therapeutic potential.\"}]","Virotherapy as Gene Deliver for Anti-Cancer Therapy - A Review Article | PDF",1790174919,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/028ab6370ada0635dcba852e7d6ae11d.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9fe72c6bc93ed8892389a58f9bb1e4c.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6d6df29e444688c7b263285528305b8.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/021f8da5c32974640e11b32cf326e963.webp",980,1385]